Advanced Medical Isotope Appoints Dr. Albert S. DeNittis to the Medical Advisory Board

KENNEWICK, WA / ACCESSWIRE / March 28, 2016 / Advanced Medical Isotope Corporation (or “AMI”) (OTC: ADMD), (www.IsotopeWorld.com) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications announced that Dr. Albert S. DeNittis MD, MS, FCPP has been appointed to the Company’s Medical Advisory Board.

Dr. Albert S. DeNittis is currently is the Chief of Radiation Oncology at Lankenau Medical Center and Clinical Professor at Lankenau Insitute for Medical Research in Wynnewood, Pennsylvania and the Director of Radiation Oncology at Brodesseur Cancer Center in New Jersey. He is also the Principal Investigator and in charge of a grant awarded by the NIH for its National Cancer Oncology Research Program (NCORP) at Main Line Health. Dr. DeNittis practice experience includes image-guided radiosurgery, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), high-dose rate (HDR) brachytherapy, cranial and extracranial stereotactic radiosurgery, respiratory gating, and Cyberknife.

Dr. DeNittis has served on numerous regional, national and government committees related to key issues in the field of oncology including the NRG Oncology group which focuses on protocol development for cancer patients on the national level. He has received regional and national awards for his research and his clinical work and authored over 100 publications and presentations as well as 6 book chapters. He has. Dr. DeNittis previously has been awarded a number of grants to study the impact of various novel oncology drugs and radiation protocols. He is a long standing member of key professional societies including the American Society of Radiation Oncology, the American Society of Clinical Oncology, and American Brachytherapy Society. Dr. DeNittis is a cofounder and board member of DermRad Therapy which is developing a multidisciplinary approach to skin cancer treatment.

Dr. DeNittis earned a BA and a MS at Rutgers University and a MD from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey. He completed postdoctoral training internships and residency at the Department of Radiation Oncology at the Hospital of the University of Pennsylvania. Dr. DeNittis is board certified by the American Board of Radiology and Licensed in New Jersey and Pennsylvania.

AMIC Founder, CEO and Chairman James C. Katzaroff stated “Dr. DeNittis has been providing valuable, uncompensated guidance to the Company for over two years on the clinical introduction and use of our yttrium-90 brachytherapy products. We are pleased to formalize our relationship with this insightful and influential radiation oncologist and increase his involvement with the Company.”

Dr. Albert S. DeNittis stated “I believe AMI’s innovative yttrium-90 brachytherapy products have incredible potential to offer significantly improved treatment options to certain patients. I am excited to advise the Company on the regulatory clearance and clinical introduction of their products.”

Dr. Albert S. DeNittis joins Chairman Dr. Barry D. Pressman MD, FACR as well as Dr. Ludwig E. Feinendegen and Dr. Darrell Fisher on the AMIC Medical Advisory Board.

About Advanced Medical Isotope Corporation:

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

Safe Harbor Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.

CONTACTS:

Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
509-736-4000

Investor Relations
Tyler M. Troup, B.Comm
Circadian Group IR, Managing Director
info@Circadian-Group.com 
866-950-8300

SOURCE: Advanced Medical Isotope Corporation

ReleaseID: 438188